Candriam S.C.A. Syndax Pharmaceuticals Inc Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Candriam S.C.A. holds 998,619 shares of SNDX stock, worth $16.8 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

998,619

Previous 970,106 2.94%

Holding current value

$16.8 Million

Previous $19.9 Million 3.48%

% of portfolio

0.11%

Previous 0.12%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$17.93 - $24.81 $511,238 - $707,407	28,513 Added 2.94%	998,619 $19.2 Million
Q2 2024 Aug 05, 2024	SELL	$18.82 - $23.79 $1.41 Million - $1.78 Million	-74,926 Reduced 7.17%	970,106 $19.9 Million
Q1 2024 May 03, 2024	BUY	$19.71 - $24.57 $473,040 - $589,680	24,000 Added 2.35%	1,045,032 $24.9 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $8.9 Million - $16.9 Million	781,022 Added 325.41%	1,021,032 $22.1 Million
Q2 2023 Aug 08, 2023	SELL	$19.35 - $22.31 $287,618 - $331,615	-14,864 Reduced 5.83%	240,010 $5.02 Million
Q1 2023 May 12, 2023	BUY	$20.66 - $28.98 $5.27 Million - $7.39 Million	254,874 New	254,874 $5.38 Million
Q2 2021 Jul 20, 2021	SELL	$13.42 - $25.18 $344,504 - $646,395	-25,671 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$15.1 - $26.44 $5.02 Million - $8.8 Million	-332,701 Reduced 92.84%	25,671 $571,000
Q3 2020 Oct 19, 2020	BUY	$13.39 - $17.48 $146,138 - $190,776	10,914 Added 3.14%	358,372 $5.29 Million
Q2 2020 Jul 23, 2020	BUY	$8.94 - $20.98 $3.11 Million - $7.29 Million	347,458 New	347,458 $5.15 Million
Q1 2018 May 09, 2018	SELL	$8.71 - $14.82 $609,700 - $1.04 Million	-70,000 Closed	0 $0
Q4 2017 Feb 07, 2018	BUY	$7.8 - $12.94 $546,000 - $905,800	70,000	70,000 $613,000

Others Institutions Holding SNDX

# of Institutions

225

Shares Held

88.2M

Call Options Held

953K

Put Options Held

653K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $950M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account